This module uses fundamental data of Bone Biologics to approximate its Piotroski F score. Bone Biologics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Bone Biologics Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Bone Biologics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Bone Biologics Altman Z Score, Bone Biologics Correlation, Bone Biologics Valuation, as well as analyze Bone Biologics Alpha and Beta and Bone Biologics Hype Analysis.
Bone
Piotroski F Score
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change In Working Capital
Sale Purchase Of Stock
Net Borrowings
Stock Based Compensation
Depreciation
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Net Debt
Cash
Cash And Short Term Investments
Liabilities And Stockholders Equity
Total Current Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Other Stockholder Equity
Total Liab
Common Stock
Short Long Term Debt Total
Other Current Assets
Short Term Debt
Net Tangible Assets
Property Plant And Equipment Net
Accounts Payable
Non Current Assets Total
Long Term Debt
Net Receivables
Non Current Liabilities Total
Inventory
Short Long Term Debt
Accumulated Other Comprehensive Income
Property Plant Equipment
Common Stock Total Equity
Property Plant And Equipment Gross
Net Invested Capital
Net Working Capital
Capital Stock
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Gross Profit
Cost Of Revenue
Depreciation And Amortization
Selling General Administrative
Research Development
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Tax Provision
Net Interest Income
Probability Of Bankruptcy
At this time, Bone Biologics' Debt Ratio is most likely to increase significantly in the upcoming years. At this time, Bone Biologics' PB Ratio is most likely to increase significantly in the upcoming years. The Bone Biologics' current EV To Operating Cash Flow is estimated to increase to 0.18, while Operating Cash Flow Per Share is projected to decrease to (43.85).
At this time, it appears that Bone Biologics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Bone Biologics is to make sure Bone is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Bone Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Bone Biologics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Bone Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Bone Biologics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
10.44
At this time, Bone Biologics' Book Value Per Share is most likely to increase significantly in the upcoming years.
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.46)
Return On Assets
(0.57)
Return On Equity
(1.19)
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.